DDx Founder Matt Leavitt and the DDx Foundation are proud to have assisted in executing this important research.

MSI is an important biomarker for immunotherapy, but due to its low prevalence in prostate cancer, molecular testing for MSI is not standard of care. Predicting MSI from routinely generated H&E stained biopsy images could therefore facilitate the identification of patients who might benefit from immunotherapy.

We’re excited about the potential of these findings and grateful to have worked with so many excellent individuals to bring forth these results.

Click the button below to access the full article.